Full Press Release Details
Nevro Announces Preliminary Unaudited Fourth Quarter and
Full Year 2018 Revenue
Calif., Jan. 7, 2019 Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its preliminary unaudited revenue for the fourth
quarter and full year ended December 31, 2018.
The company announced that preliminary unaudited fourth quarter 2018 worldwide revenue is expected to be in the range of $107.6 to $108.1 million,
compared to $98.0 million in the prior year quarter. Preliminary unaudited U.S. revenue for the fourth quarter of 2018 is expected to be in the range of $91.5 to $91.8 million, compared to $81.1 million in the prior year quarter.
Preliminary unaudited international revenue for the fourth quarter of 2018 is expected to be in the range of $16.1 to $16.3 million, compared to $16.9 million in the prior year quarter.
Nevro s preliminary unaudited full
year 2018 revenue is expected to be in the range of $386.9 to $387.4 million, compared to $326.7 million in the prior year. Preliminary unaudited U.S. revenue for the full year 2018 is expected to be in the range of $321.6 to
$321.9 million, compared to $263.5 million in the prior year. Preliminary unaudited international revenue for the full year 2018 is expected to be in the range of $65.3 to $65.5 million, compared to $63.2 million in the prior
Nevro s CEO Rami Elghandour will be presenting at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at
10:30 am pacific time. The investor presentation materials are available now on the Investors section of the company s website at www.nevro.com, and the live presentation on January 9th will be webcast and archived there.
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life
of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for
the treatment of chronic pain. The Senza System and Senza II System are the only SCS systems that deliver Nevro s proprietary
HF10 therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.
Forward-Looking Statements
In addition to historical
information, this press release contains forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the
Company s expectations for its fourth quarter and full year 2018 worldwide, U.S. and international revenue; and its expectations for worldwide revenue for the full year 2018. These forward-looking statements are based upon information that is
currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; our ability to manufacture our products
to meet demand; the level and availability of third-party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our
ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified
personnel; and product liability claims. These factors, together with those that are described in greater detail in our Annual Report on Form 10-K filed on February 22, 2018 and our Quarterly Report on
Form 10-Q filed on November 5, 2018, as well as any reports that we may file with the Securities and Exchange Commission in the future, may cause our actual results, performance or achievements to differ
materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. Our preliminary
operating results for the quarter and full year ended December 31, 2018 are subject to adjustment as we complete our year-end audit and other processes and are not necessarily indicative of our operating
results for any future periods.
Nevro Investor Relations